Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC × Immune Checkpoint Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 37 Carcinoma, Hepatocellular 24 Stomach Neoplasms 12 Melanoma 12 Neoplasms 11 Neoplasm Metastasis 11 Colorectal Neoplasms 11 Triple Negative Breast Neoplasms 9 Esophageal Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 7 Recurrence 7 Nasopharyngeal Carcinoma 7 Head and Neck Neoplasms 7 Biliary Tract Neoplasms 7 Esophageal Squamous Cell Carcinoma 6 Carcinoma, Renal Cell 6 Pancreatic Neoplasms 5 Lung Neoplasms 5 Colonic Neoplasms 5 Breast Neoplasms 5 Small Cell Lung Carcinoma 4 Cholangiocarcinoma 4 Advanced NSCLC 4 Urinary Bladder Neoplasms 3 Rectal Neoplasms 3 Ovarian Neoplasms 3 Liver Neoplasms 3 Hyperthermia 3 Uterine Cervical Neoplasms 2 Turcot syndrome 2

Interventions

Paclitaxel 2 Etoposide 2 Carboplatin 2 sintilimab 1 atezolizumab 1 apatinib 1 Topotecan 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07110103 2026-02-27

JACKPOT38

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡